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Autoxidation products of both carbohydrates and lipids are
increased in uremic plasma: Is there oxidative stress in uremia?
Background. Advanced glycation end products (AGEs), formed
by non-enzymatic glycation and oxidation (glycoxidation) reac-
tions, have been implicated in the pathogenesis of several dis-
eases, including normoglycemic uremia. AGE research in uremia
has focused on the accumulation of carbohydrate-derived adducts
generated by the Maillard reaction. Recent studies, however, have
demonstrated that one AGE, the glycoxidation product car-
boxymethyllysine (CML), could be derived not only from carbo-
hydrates but also from oxidation of polyunsaturated fatty acids in
vitro, raising the possibility that both carbohydrate and lipid
autoxidation might be increased in uremia.
Methods. To address this hypothesis, we applied gas chroma-
tography-mass spectrometry and high performance liquid chro-
matography to measure protein adducts formed in uremic plasma
by reactions between carbonyl compounds and protein amino
groups: pentosidine derived from carbohydrate-derived carbonyls,
malondialdehyde (MDA)-lysine derived from lipid-derived car-
bonyls, and CML originating possibly from both sources.
Results. All three adducts were elevated in uremic plasma.
Plasma CML levels were mainly (.95%) albumin bound. Their
levels were not correlated with fructoselysine levels and were
similar in diabetic and non-diabetic patients on hemodialysis,
indicating that their increase was not driven by glucose. Pentosi-
dine and MDA-lysine were also increased in plasma to the same
extent in diabetic and non-diabetic hemodialysis patients. Statis-
tical analysis indicated that plasma levels of CML correlated
weakly (P , 0.05) with those of pentosidine and MDA-lysine, but
that pentosidine and MDA-lysine varied independently (P . 0.5).
Conclusions. These data suggest that the increased levels of
AGEs in blood, and probably in tissues, reported in uremia
implicate a broad derangement in non-enzymatic biochemistry
involving alterations in autoxidation of both carbohydrates and
lipids.
Proteins in the body are continuously modified by non-
enzymatic glycation and oxidation (glycoxidation) reac-
tions, also known as Maillard or browning reactions. Schiff
base and Amadori adducts between protein amino groups
and carbohydrate-derived carbonyls eventually yield ad-
vanced glycation end products (AGEs) [1]. AGE modified
proteins increase during normal aging, but markedly in-
crease in diabetes and uremia, damaging tissues through
alterations of their structure and function [1], and stimula-
tion of pathologic cellular responses [2–6].
The availability of sensitive and specific methods to
identify some of the AGEs generated on proteins during
the Maillard reaction has helped unravel the various path-
ways leading to the formation of AGEs in uremia. In vitro
studies have demonstrated that pentosidine [7] originates
from glucose-, ribose-, or ascorbic acid-derived carbonyl
intermediates [8–11]. Similarly, Ne-(carboxymethyl)lysine
(CML) [12] is formed on proteins exposed to glucose or
ascorbic acid under oxidative condition [10–13]. Both
compounds have been taken as markers of carbohydrate-
derived AGE adducts. More recently, however, similar in
vitro studies have demonstrated that CML can also be
derived from lipid sources such as polyunsaturated fatty
acids [14], raising the possibility that AGE adducts arise
from carbonyl compounds derived from both carbohydrates
and lipids.
To test this hypothesis, we have measured in uremic
plasma several stable protein adducts formed by reactions
between carbonyl compounds and lysine amino groups in
proteins [15]: pentosidine originating from carbohydrate-
derived carbonyls, malondialdehyde (MDA)-lysine from
lipid-derived carbonyls [16], and CML originating possibly
from both carbohydrates and lipids. Our results show that
there are significant increases in all three compounds,
suggesting that the increased levels of AGEs in uremic
patients, whether detected by immunohistochemical [11] or
enzyme-linked immunosorbent assay (ELISA) techniques
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[17], result from a broad derangement in non-enzymatic
biochemistry in uremia, involving alterations in autoxida-
tion of both carbohydrates and lipids.
METHODS
Plasma samples
Plasma was obtained from 9 normal subjects with normal
renal function and no proteinuria (Group I in Table 1), and
25 non-diabetic (Group II) and 21 diabetic patients under-
going hemodialysis (Group III). Characteristics of the study
population are summarized in Table 1. None of the patients
were on lipid lowering drugs. Informed consent was ob-
tained from all patients. Normal renal function was defined
as a serum creatinine level below 1.0 mg/dl. Proteinuria was
considered to be absent if no protein was detectable in the
urine with Albustix (Bayer-Sankyo, Tokyo, Japan). Hemo-
dialysis was performed three times weekly for four hours
with a dialysate containing 2 g/liter glucose, 30 mmol/liter
bicarbonate, and 8 mmol/liter acetate. Plasma protein
concentration was determined in fresh heparinized plasma
using the Bio-Rad protein assay reagent (Richmond, CA,
USA) with human albumin as a standard. Fractionation of
plasma proteins was performed by gel filtration on a
Sephacryl S-200 column (5.0 3 67 cm; Pharmacia, Uppsala,
Sweden). Plasma triglycerides and creatinine were mea-
sured by routine methods at the central laboratory of Tokai
University Hospital.
Materials
Unless otherwise indicated, reagents were of highest
quality obtainable from Sigma (St. Louis, MO, USA). The
preparation of fructoselysine, CML, pentosidine, and
MDA-lysine standards have been described previously [14,
18, 19].
Analytical procedure
For measurement of CML and MDA-lysine, plasma
samples (75 ml) were diluted with 75 ml 0.2 M sodium
borate, pH 9.2, followed by addition of 15 ml 5.5 M NaBH4
in 0.1 N NaOH (final 500 mM BH4). Reduction was carried
out at 4°C overnight and then protein precipitated by
addition of an equal volume of 20% trichloroacetic acid.
Protein was pelleted by centrifugation at 2000 3 g for three
to five minutes. The supernatant was discarded and the
pellet washed with 300 ml 10% trichloroacetic acid. Heavy
labeled internal standards were added and the sample
hydrolyzed in 3 ml 6 N HCl at 110°C for 24 hours.
Fructoselysine was analyzed in a separate 75 ml aliquot of
plasma prepared as above except that the reduction step
was omitted. The hydrolysates were dried by centrifugal
evaporation (Savant Speed Vac, Farmingdale, NY, USA).
Fructoselysine, CML, MDA-lysine, and lysine in plasma
hydrolysates were measured as their N,O-trifluoroacetyl
methyl esters by selected-ion monitoring gas chromatogra-
phy/mass spectrometry (GC/MS), as described previously
[14, 18, 19]. Analytes were normalized to the lysine content
of the sample, following external standardization using
calibration curves generated from solutions containing
constant amounts of heavy labeled standards and increas-
ing amounts of unlabeled standard.
Pentosidine was measured in hydrolysates of separate
plasma samples after reduction, precipitation and acid
hydrolysis as above, except that the final concentration of
borohydride used for reduction was decreased to 100 mM.
Hydrolysates were dried, dissolved in 10 ml water and
applied to a 1 ml SP-Sephadex C-25 (Pharmacia Biotech)
column equilibrated in water. The sample eluate was
discarded. The column was next eluted with 20 ml 0.1 N
HCl, and this eluate was also discarded. Pentosidine was
eluted with 5 ml 0.1 N HCl. The eluate was dried and an
aliquot then used for quantification of pentosidine by
reversed-phase high performance liquid chromatography
(HPLC) using post-column fluorescence detection (Ex 5
328 nm, Em 5 378 nm), as described previously [19]. A
second aliquot of the SP-Sephadex eluate was used to
measure lysine content by amino acid analysis, and pento-
sidine concentration was expressed relative to lysine con-
tent.
All samples assayed in this study were analyzed in single
batches to exclude interassay variation. Intraassay coeffi-
cients of variation of the assays were determined by repeat
analyses (N 5 5) of low (normal) and high (uremic) sample
pools. Coefficients of variation ranged from 5 to 15% for
the various assays, where the lower number refers to the
Table 1. Profile of subjects examined in this study
Group I Normal subjects
(N 5 9)
Group II Non-diabetic
HD patients (N 5 25)
Group III Diabetic
HD patients (N 5 21)
Age years 43.5 6 8.1 60.6 6 9.9a 62.0 6 9.1a
Total protein g/dl 7.90 6 0.32 7.28 6 0.46b 7.16 6 0.48a
Serum creatinine mg/dl 0.81 6 0.11 10.73 6 2.19c 10.10 6 2.25a
Fructoselysine mmol/mol Lys 2.27 6 0.17 2.50 6 0.58 4.33 6 1.14c
Triglycerides mg/dl 88.8 6 70.5 122.0 6 91.2 121.7 6 80.0
HD is hemodialysis.
a P , 0.001 vs normal subjects
b P , 0.01 vs normal subjects
c P , 0.001 vs. normal and non-diabetic HD subjects
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coefficients of variation for the high standard and the
higher number refers to the coefficients of variation for the
low standard: pentosidine, 5 to 13%; CML, 5 to 9%; and
MDA-lysine, 9 to 15%.
Statistical analysis
Data are expressed as means 6 SD. The Student’s t-test
was used for a statistical evaluation of significant difference
between the two groups. Correlation was assessed by linear
regression analysis.
RESULTS
As shown in Table 1, hemodialysis patients had slightly
lower protein and significantly higher serum creatinine
concentrations. Neither of these measures differed be-
tween the non-diabetic and diabetic hemodialysis patients.
Fructoselysine was increased approximately two-fold in
diabetic hemodialysis patients but was unchanged in non-
diabetic hemodialysis patients, compared to controls. Trig-
lycerides were similar in all three groups.
Results of measurement of CML, pentosidine and
MDA-lysine in plasma are shown in Figure 1. Plasma CML
levels (Fig. 1A) of non-diabetic (Group II in Table 1) and
diabetic hemodialysis patients (Group III) were signifi-
cantly higher than those of normal subjects (Group I)
(0.313 6 0.065 and 0.342 6 0.090 vs. 0.090 6 0.016
mmol/mol Lys, respectively, P , 0.0001). They were not
significantly different between the non-diabetic and dia-
betic hemodialysis patients, a finding interpreted as evi-
dence that CML accumulation is not driven by increased
glucose concentrations. This conclusion is also supported
by the lack of correlation between CML and fructoselysine
(Fig. 2A). Thus, fructoselysine is a known precursor of
CML in vitro, and its concentration was increased about
twofold in the diabetic hemodialysis patients (Table 1).
Plasma pentosidine levels (Fig. 1B) of non-diabetic and
diabetic hemodialysis patients were also significantly higher
than those of normal subjects (11.12 6 5.46 and 14.02 6
7.04 vs. 1.13 6 0.36 mmol/mol Lys, respectively, P ,
0.0001). They were not significantly different between
non-diabetic and diabetic hemodialysis patients. Levels of
pentosidine did not correlate with blood glucose or fruc-
toselysine.
CML and pentosidine, both glycoxidation products, were
significantly correlated with each other in all hemodialysis
patients (Fig. 2B). In order to determine which plasma
protein fraction(s) was post-translationally modified with
CML, plasma was fractionated by gel filtration and the
CML content was determined in the albumin and IgG
fractions of a pooled plasma sample. CML values for total
plasma, albumin, and IgG were 0.306, 0.576, 0.189 mmol/
mol Lys, respectively. Since albumin constitutes the major
Fig. 1. Plasma Ne-(carboxymethyl)lysine (CML), pentosidine, and MDA-lysine levels in normal and hemodialysis subjects. CML (A), pentosidine (B),
and malondialdehyde (MDA)-lysine (C) levels in acid hydrolysates of plasma from normal subjects (Group I, N 5 9), non-diabetic hemodialysis patients
(Group II, N 5 25), and diabetic hemodialysis patients (Group III, N 5 21), were determined by GC/MS or HPLC assay (detailed in Methods section).
Data are expressed as means 6 SD. *P , 0.0001 versus normal subjects. NS is not significant.
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protein in plasma (;40 mg albumin out of ;70 mg total
plasma protein/ml), these data indicate that over 95% of
plasma CML is associated with the albumin fraction, a
finding similar to that previously reported for pentosidine
[20].
Levels of MDA-lysine levels (Fig. 1C) in plasma proteins
of non-diabetic and diabetic hemodialysis patients were
also significantly higher than those of normal subjects
(0.037 6 0.009 and 0.033 6 0.008 vs. 0.019 6 0.005
mmol/mol Lys, respectively, P , 0.0001). Like CML and
pentosidine, they were not significantly different between
diabetic and non-diabetic hemodialysis patients. Levels of
MDA-lysine were not correlated with those of triglycerides
in hemodialysis patients (r 5 20.329, P 5 0.467).
Plasma levels of CML, but not pentosidine (Fig. 3A),
were correlated with MDA levels in hemodialysis patients
(Fig. 3B), although levels of CML and pentosidine were
correlated weakly with one another.
DISCUSSION
Research on AGEs in uremia has focused on the accu-
mulation of carbohydrate-derived adducts generated by the
Maillard reaction, such as, AGE-peptides [17, 21], pento-
sidine [20, 22, 23], and CML [24]. We have recently
presented evidence that AGE generation in uremic plasma
is stimulated by the accumulation of carbonyl intermediates
resulting from the oxidation of glucose and ascorbic acid
[11, 25]. We now demonstrate the parallel accumulation of
another carbonyl compound, MDA, derived from lipid
peroxidation. The accumulation in uremic circulation of
carbonyl intermediates derived from various sources, such
as carbohydrates, ascorbic acids, and lipids, may be de-
scribed as “carbonyl stress.”
The finding of elevated levels of MDA-lysine in uremic
sera is of interest. Only indirect evidence on changes in
MDA are available, based on measurement of thiobarbitu-
ric acid reactive substances (TBARS) whose levels were
reported to be either elevated [26] or normal [27] in uremic
sera. TBARS measurements are not specific for MDA as
they include several other compounds, depending on assay
conditions, including prostaglandin and leukotriene metab-
olites [28]. The present GC/MS methodology is highly
sensitive and specific for MDA-lysine adducts in proteins.
Unlike TBARS, it evaluates actual protein modification
Fig. 2. (A) Correlation between plasma CML
and fructoselysine in hemodialysis patients.
Plasma CML levels were not correlated with
those of fructoselysine in hemodialysis subjects
(N 5 46, r 5 0.186, P 5 0.216). The equation
of the line is y 5 3.022x 1 2.345. (B)
Correlation between plasma CML and
pentosidine in hemodialysis patients. Plasma
CML levels were correlated with those of
pentosidine in hemodialysis subjects (N 5 46,
r 5 0.430, P , 0.01). The equation of the line
is y 5 34.86x 1 1.07.
Fig. 3. (A) Correlation between plasma
pentosidine and MDA-lysine in hemodialysis
patients. Plasma pentosidine levels were not
correlated with those of MDA-lysine in
hemodialysis subjects (N 5 46, r 5 0.097, P 5
0.522). The equation of the line is y 5 0.00013x
1 0.033. (B) Correlation between plasma CML
and MDA-lysine in hemodialysis patients.
Plasma CML levels were correlated with those
of MDA-lysine in hemodialysis subjects (N 5
46, r 5 0.320, P , 0.05). The equation of the
line is y 5 0.035x 1 0.023.
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resulting from lipid peroxidation. Although the polyunsat-
urated fatty acid composition of plasma was not measured
in this study, the lack of a relationship between triglyceride
levels and MDA-lysine or CML, among all subjects, sug-
gests that increased polyunsaturated fatty acid oxidation
was a major contributor to MDA-lysine formation.
The weak correlations of CML with MDA-lysine, and
CML with pentosidine suggests that CML is derived not
only from carbohydrate-autoxidation products of the Mail-
lard reaction, but also from lipid peroxidation products. Fu
et al recently demonstrated the generation of CML from
polyunsaturated fatty acids [14]. The lack of correlation
between MDA-lysine and pentosidine is consistent with the
observation that pentosidine originates solely from carbo-
hydrate [8, 9] and MDA-lysine from lipid peroxidation. In
addition to MDA, a wide variety of other lipid-derived
carbonyl compounds might react with proteins and deserve
further study [29].
AGEs such as pentosidine and CML, as well as MDA-
lysine, are formed by carbonyl-amine chemistry between
protein amino- and guanidino-groups and carbohydrate- or
lipid-derived carbonyl compounds. The identity of the
carbonyl compounds accumulating in uremia remains a
matter of speculation. Several substances are probably
involved as no single carbonyl precursor is known to result
in the simultaneous formation of CML, pentosidine, and
MDA-lysine. The lack of difference between diabetic and
non-diabetic uremic plasma suggests that it is not glucose.
It cannot be ascorbate/dehydroascorbate whose level is
decreased in uremic plasma [11]. Another intermediate
compound formed during Maillard reaction, 3-deoxyglu-
cosone, is known to accumulate in uremia [30], but is
unlikely to be a candidate. Addition of 3-deoxyglucosone to
normal plasma, even at concentrations higher than those
reported in uremic subjects, failed to raise pentosidine
concentrations during in vitro incubation [25].
The present results demonstrate that, like pentosidine,
over 90% of CML is bound to albumin. The two best
characterized AGE adducts are thus associated with high
molecular weight substances in the serum, a finding in
contrast to that reported for immunologically detected
AGE-peptides (molecular weight, , 10 kD) [17]. Although
most, if not all polyclonal anti-AGE antibodies recognize
CML [31, 32], the one used in studies of AGE-peptides
apparently recognizes another as yet unknown epitope.
Until the identity of the epitope, as well as the origin of
these small fragments are elucidated, it will be difficult to
integrate immunological observations into a broader view
of carbonyl stress in uremia.
The reasons for the elevation of carbonyl compounds in
uremia remain to be elucidated. It might be due to the
retention of various metabolites as a result of kidney
failure, that is, either defective catabolism through glomer-
ular filtration and subsequent tubular reabsorption and
destruction as demonstrated for pentosidine [33] or im-
paired removal through urinary excretion.
Alternatively, a uremia-associated oxidative stress [34–
39] might augment the production of carbonyl compounds
as already suggested for CML generation from glyoxal or
dehydroascorbate, and for pentosidine generation from
arabinose or dehydroascorbate [10, 11]. The respective
contributions of these two pathways require further clari-
fication.
Whatever the identity of the carbonyl compounds and
the mechanisms of their rise in uremia, we suggest that
identifying the various AGE adducts as well as MDA-lysine
as “carbonyl stress end products” underlies that the non-
enzymatic modifications disorders observed in uremia ex-
tend beyond the borders of carbohydrate-derived Maillard
reaction adducts.
ACKNOWLEDGMENTS
This study was supported by Research for the Future Program of the
Japan Society for the Promotion of Science grant (96L00303) to TM,
United States Public Health Service grants (NIDDK 19971) to JWB and
(AG11472, P01-HL55782) to SRT, and a Juvenile Diabetes Foundation
International grant to SRT.
Reprint requests to Toshio Miyata, M.D., Ph.D., Molecular and Cellular
Nephrology, Institute of Medical Sciences and Department of Internal




Abbreviations used in this paper: AGEs, advanced glycation end
products; CML, Ne-(carboxymethyl)lysine; ELISA, enzyme-linked im-
monosorbent assay; GC/MS, gas chromatography/mass spectrometry;
HPLC, high-performance liquid chromatography; MDA, malondialde-
hyde; TBARS, thiobarbituric acid reactive substances.
REFERENCES
1. BROWNLEE M, CERAMI A, VLASSARA H: Advanced glycosylation end
products in tissue and the biochemical basis of diabetic complications.
N Engl J Med 318:1315–1321, 1988
2. KIRSTEIN M, BRETT J, RADOFF S, OGAWA S, STERN D, VLASSARA H:
Advanced protein glycosylation induces transendothelial human
monocyte chemotaxis and secretion of platelet-derived growth factor:
Role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA
87:9010–9014, 1990
3. VLASSARA H, BROWNLEE M, MANOGUE KR, DINARELLO CA, PASA-
GIAN A: Cachectin/TNF and IL-1 induced by glucose-modified pro-
teins: Role in normal tissue remodeling. Science 240:1546–1548, 1988
4. MIYATA T, INAGI R, IIDA Y, SATO M, YAMADA N, ODA O, MAEDA K,
SEO H: Involvement of b2-microglobulin modified with advanced
glycation end products in the pathogenesis of hemodialysis-associated
amyloidosis: Induction of human monocyte chemotaxis and macro-
phage secretion of tumor necrosis factor-a and interleukin 1. J Clin
Invest 93:521–528, 1994
5. MIYATA T, HORI O, ZHANG JH, YAN SD, FERRAN L, IIDA Y, SCHMIDT
AM: The receptor for advanced glycation endproducts mediates the
interaction of AGE-b2-microglobulin with human mononuclear
phagocytes via an oxidant-sensitive pathway: Implication for the
pathogenesis of dialysis-related amyloidosis. J Clin Invest 98:1088–
1094, 1996
6. MIYATA T, NOTOYA K, YOSHIDA K, HORIE K, KUROKAWA K, MAEDA
K, TAKETOMI S: Advanced glycation end products enhance osteoclast-
induced bone resorption in cultured mouse unfractionated bone cells
Miyata et al: Carbonyl stress in uremia1294
and in rats implanted subcutaneously with devitalized bone particles.
J Am Soc Nephrol 8:260–270, 1997
7. SELL DR, MONNIER VM: Structure elucidation of a senescence
cross-link from human extracellular matrix. J Biol Chem 264:21597–
21602, 1989
8. GRANDHEE SK, MONNIER VM: Mechanism of formation of the
Maillard protein cross-link pentosidine. J Biol Chem 266:11649–
11653, 1991
9. DYER DG, BLACKLEDGE JA, THORPE SR, BAYNES JW: Formation of
pentosidine during nonenzymatic browning of protein by glucose:
Identification of glucose and other carbohydrates as possible precur-
sors of pentosidine in vivo. J Biol Chem 266:11654–11660, 1991
10. WELLS-KNECHT KJ, ZYZAK DV, LITCHFIELD JE, THORPE SR, BAYNES
JW: Mechanism of autoxidative glycosylation: Identification of glyoxal
and arabinose as intermediates in the autoxidative modification of
protein by glucose. Biochemistry 34:3702–3709, 1995
11. MIYATA T, WADA Y, CAI Z, IIDA Y, HORIE K, YASUDA Y, MAEDA K,
KUROKAWA K, VAN YPERSELE DE STRIHOU C: Implication of an
increased oxidative stress in the formation of advanced glycation end
products in patients with end-stage renal failure. Kidney Int 51:1170–
1181, 1997
12. AHMED MU, THORPE SR, BAYNES JW: Identification of Ne-carboxym-
ethyllysine as a degradation product of fructoselysine in glycated
protein. J Biol Chem 261:4889–4894, 1986
13. DUNN JA, AHMED MU, MURTIASHAW MH, RICHARDSON JM, WALLA
MD, THORPE SR, BAYNES JW: Reaction of ascorbate with lysine and
protein under autoxidizing conditions: Formation of Ne-(carboxy-
methyl)lysine by reaction between lysine and products of autoxidation
of ascorbate. Biochemistry 29:10964–10970, 1990
14. FU MX, REQUENA JR, JENKINS AJ, LYONS TJ, BAYNES JW, THORPE
SR: The advanced glycation end product, Ne-(carboxymethyl)lysine, is
a product of lipid peroxidation and glycoxidation reactions. J Biol
Chem 271:9982–9986, 1996
15. MIYATA T, VAN YPERSELE DE STRIHOU C, KUROKAWA K, BAYNES JW:
Alterations in non-enzymatic biochemistry in uremia: Origin and
significance of “carbonyl stress” in long-term uremic complications.
Kidney Int (in press)
16. ESTERBAUER H, SCHAUR RJ, ZOLLNER H: Chemistry and biochemistry
of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free
Rad Biol Med 11:81–128, 1991
17. MAKITA Z, VLASSARA H, CERAMI A, BUCALA R: Immunochemical
detection of advanced glycosylation end products in vivo. J Biol Chem
267:5133–5138, 1992
18. REQUENA JR, FU MX, AHMED MU, JENKINS AJ, LYONS TJ, BAYNES
JW, THORPE SR: Quantification of malondialdehyde and 4-hy-
droxynonenal adducts to lysine residues in native and oxidized human
low-density lipoprotein. J Biol Chem 322:317–325, 1997
19. DYER DG, DUNN JA, THORPE SR, BAILIE KE, LYONS TJ, MCCANCE
DR, BAYNES JW: Accumulation of Maillard reaction products in skin
collagen in diabetes and aging. J Clin Invest 91:2463–2469, 1993
20. MIYATA T, UEDA Y, SHINZATO T, IIDA Y, TANAKA S, KUROKAWA K,
VAN YPERESLE DE STRIHOU C, MAEDA K: Accumulation of albumin-
linked and free-form pentosidine in the circulation of uremic patients
with end-stage renal failure: Renal implications in the pathophysiol-
ogy of pentosidine. J Am Soc Nephrol 7:1198–1206, 1996
21. MAKITA Z, RADOFF S, RAYFIELD EJ, YANG Z, SKOLNIK E, DELANEY
V, FRIEDMAN EA: Advanced glycosylation end products in patients
with diabetic nephropathy. N Engl J Med 325:836–842, 1991
22. ODETTI P, FORGARTY J, SELL DR, MONNIER VM: Chromatographic
quantitation of plasma and erythrocyte pentosidine in diabetic and
uremic subjects. Diabetes 41:153–159, 1992
23. MIYATA T, TANEDA S, KAWAI R, UEDA Y, HORIUCHI S, HARA M,
MAEDA K, MONNIER VM: Identification of pentosidine as a native
structure for advanced glycation end products in b2-microglobulin-
containing amyloid fibrils in patients with dialysis-related amyloidosis.
Proc Natl Acad Sci USA 93:2353–2358, 1996
24. DEGENHARDT TP, GRASS L, REDDY S, THORPE SR, DIAMANDIS EP,
BAYNES JW: The serumconcentration of the advanced glycation
end-product Ne-(carboxymethyl)lysine is increased in uremia. Kidney
Int 52:1064–1067, 1997
25. MIYATA T, UEDA Y, YAMADA Y, IZUHARA Y, SAITO A, JADOUL M,
KUROKAWA K, VAN YPERSELE DE STRIHOU C: Accumulation of
carbonyls accelerate the formation of pentosidine, an advanced
glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol (in
press)
26. DASGUPTA A, HUSSAIN S, AHMAD S: Increased lipid peroxidation in
patients on maintenance hemodialysis. Nephron 60:56–59, 1992
27. PAUL JL, SALL ND, SONI T, POIGNET JL, LIDENBAUM A, MAN NK,
MOATTI N, RAICHVARG D: Lipid peroxidation abonormalities in
hemodialyzed patients. Nephron 64:106–109, 1993
28. JANERO DR: Malondialdehyde and thiobarbituric acid-reactivity as
diagnostic indices of lipid peroxidation and peroxidative tissue injury.
Free Rad Bio Med 9:515–540, 1990
29. ZAMORA R, ALAIZ M, HIDALGO FJ: Feedback inhibition of oxidative
stress by oxidized lipid/amino acid reaction products. Biochemistry
36:15765–15771, 1997
30. NIWA T, KATSUZAKI T, MOMOI T, MIYAZAKI T, OGAWA H, SAITO A,
MIYAZAKI S, MAEDA K, TATEMICHI N, TAKEI Y: Modification of b2m
with advanced glycation end products as observed in dialysis-related
amyloidosis by 3-DG accumulating in uremic serum. Kidney Int
49:861–867, 1996
31. REDDY S, BICHLER J, WELLS-KNECHT KJ, THORPE SR, BAYNES JW:
Ne-(carboxymethyl)lysine is a dominant advanced glycation end prod-
uct (AGE) antigen in tissue proteins. Biochemistry 34:10872–10878,
1995
32. TAKEDA A, YASUDA T, MIYATA T, MIZUNO K, LI M, YONEYAMA S,
HORIE K, MAEDA K, SOBUE G: Immunohistochemical study of
advanced glycation end products in aging and Alzheimer’s disease
brain. Neurosci Lett 221:17–20, 1996
33. MIYATA T, UEDA Y, HORIE K, NANGAKU M, TANAKA S, VAN
YPERSELE DE STRIHOU C, KUROKAWA K: Renal catabolism of ad-
vanced glycation end products: The fate of pentosidine. Kidney Int
53:416–422, 1998
34. MIYATA T, MAEDA K, KUROKAWA K, VAN YPERSELE DE STRIHOU C:
Oxidation conspires with glycation to generate noxious advanced
glycation end products in renal failure. Nephrol Dial Transplant
12:255–258, 1997
35. CANESTRARI F, GALLI F, GIORGINI A, ALBERTINI MC, GALIOTTA P,
PASCUCCI M, BOSSU M: Erythrocyte redox state in uremic anemia:
Effects of hemodialysis and relevance of glutathione metabolism. Acta
Haematol 91:187–193, 1994
36. YEUNG JH: Effects of glycerol-induced acute renal failure on tissue
glutathione and glutathione-dependent enzymes in the rat. Methods
Find Exp Clin Pharmacol 13:23–28, 1991
37. KUMANO K, YOKOTA S, GO M, SUYAMA K, SAKAI T, ERA S, SOGAMI
M: Quantitative and qualitative changes of serum albumin in CAPD
patients. Adv Perit Dial 8:127–130, 1992
38. WITKO-SARSAT V, FRIEDLANDER M, CAPEILLERE-BLANDIN C, CA-
PEILLERE-BLANDIN C, NGUYEN-KHOA T, NGUYEN AN, ZINGRAFF J,
JUNGERS P, DESCAMPS-LATSCHA B: Advanced oxidation protein prod-
ucts as a novel marker of oxidative stress in uremia. Kidney Int
49:1304–1313, 1996
39. ODETTI P, GARIBALDI S, GURRERI G, ARAGNO I, DAPINO D,
PRONZATO MA: Protein oxidation in hemodialysis and kidney trans-
plantation. Metabolism 45:1319–1322, 1996
Miyata et al: Carbonyl stress in uremia 1295
